© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
May 28, 2022
The organizations that can take on 2-sided risk are usually bigger and that’s not always better for health care, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
May 27, 2022
Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
May 26, 2022
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.
Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.
May 24, 2022
There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.
The logistics for storing chimeric antigen receptor (CAR) T-cell therapies remain a challenge, said Joel Wayment, vice president of operations for 3PL Services, Cardinal Health.
May 18, 2022
Across commercial insurance, Medicare, and Medicaid populations, oncology is the top category of spend, and the drug pipeline has increasing specific and complex therapies.
May 16, 2022
While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
May 13, 2022
Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.
While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.